Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,024 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, Alex AA, Ganesan S, Lakshmi KM, Sitaram U, Nair SC, Chandy M, Janet NB, Srivastava VM, Srivastava A, Mathews V. Chendamarai E, et al. Among authors: ganesan s. Blood. 2012 Apr 12;119(15):3413-9. doi: 10.1182/blood-2011-11-393264. Epub 2012 Feb 28. Blood. 2012. PMID: 22374701 Free article.
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Chendamarai E, Ganesan S, Alex AA, Kamath V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM, Viswabandya A, Abraham A, Aiyaz M, Mullapudi N, Mugasimangalam R, Padua RA, Chomienne C, Chandy M, Srivastava A, George B, Balasubramanian P, Mathews V. Chendamarai E, et al. Among authors: ganesan s. PLoS One. 2015 Mar 30;10(3):e0121912. doi: 10.1371/journal.pone.0121912. eCollection 2015. PLoS One. 2015. PMID: 25822503 Free PMC article.
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis.
Alex AA, Ganesan S, Palani HK, Balasundaram N, David S, Lakshmi KM, Kulkarni UP, Nisham PN, Korula A, Devasia AJ, Janet NB, Abraham A, Srivastava A, George B, Padua RA, Chomienne C, Balasubramanian P, Mathews V. Alex AA, et al. Among authors: ganesan s. Front Immunol. 2018 Jun 14;9:1357. doi: 10.3389/fimmu.2018.01357. eCollection 2018. Front Immunol. 2018. PMID: 29963052 Free PMC article.
Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population.
David S, Nair SC, Singh GS, Alex AA, Ganesan S, Palani HK, Balasundaram N, Lakshmi KM, Joshi A, Kannan S, Korula A, Nambiatheyil Aboobacker F, Abraham A, George B, Apte SJ, Srivastava A, Mathews V. David S, et al. Among authors: ganesan s. Haemophilia. 2019 Jan;25(1):67-74. doi: 10.1111/hae.13633. Epub 2018 Nov 14. Haemophilia. 2019. PMID: 30427567
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
Kulkarni U, Ganesan S, Alex AA, Palani H, David S, Balasundaram N, Venkatraman A, Thenmozhi M, Jeyaseelan L, Korula A, Devasia A, Abraham A, Janet NB, Balasubramanian P, George B, Mathews V. Kulkarni U, et al. Among authors: ganesan s. Cancer Med. 2020 Apr;9(8):2603-2610. doi: 10.1002/cam4.2883. Epub 2020 Feb 14. Cancer Med. 2020. PMID: 32059085 Free PMC article. Clinical Trial.
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
Fouzia NA, Sharma V, Ganesan S, Palani HK, Balasundaram N, David S, Kulkarni UP, Korula A, Devasia AJ, Nair SC, Janet NB, Abraham A, Mani T, Lakshmanan J, Balasubramanian P, George B, Mathews V. Fouzia NA, et al. Among authors: ganesan s. Br J Haematol. 2021 Jan;192(2):292-299. doi: 10.1111/bjh.17221. Epub 2020 Nov 20. Br J Haematol. 2021. PMID: 33216980 Free PMC article.
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N, Ganesan S, Chendamarai E, Palani HK, Venkatraman A, Alex AA, David S, Kumar SP, Radhakrishnan NR, Yasar M, Krishna S, Korula A, Kulkarni U, Janet NB, Balasubramanian P, Mathews V. Balasundaram N, et al. Among authors: ganesan s. Blood Adv. 2022 Jan 25;6(2):652-663. doi: 10.1182/bloodadvances.2021005300. Blood Adv. 2022. PMID: 34625794 Free PMC article.
1,024 results